HC Wainwright Reaffirms “Buy” Rating for Candel Therapeutics (NASDAQ:CADL)
Candel Therapeutics (NASDAQ:CADL – Get Free Report)‘s stock had its “buy” rating restated by equities researchers at HC Wainwright in a research note issued to investors on Friday,Benzinga reports. They currently have a $19.00 price target on the stock. HC Wainwright’s target price would indicate a potential upside of 117.14% from the stock’s current price. […]
Candel Therapeutics (NASDAQ:CADL – Get Free Report)‘s stock had its “buy” rating restated by equities researchers at HC Wainwright in a research note issued to investors on Friday,Benzinga reports. They currently have a $19.00 price target on the stock. HC Wainwright’s target price would indicate a potential upside of 117.14% from the stock’s current price. […]
